Strong Sobi presence at American Society of Hematology 2020 Annual Meeting
Sobi™ will present data at the 62nd Annual Meeting of the American Society of Hematology (ASH) taking place taking place as a virtual meeting from 5-8 December. Twelve abstracts featuring five treatments have been accepted for presentation during ASH, reflecting Sobi’s commitment to the rare disease community. Final data in previously untreated patients with haemophilia Final data strengthening evidence for the efficacy and safety of Elocta® (efmoroctocog alfa) and Alprolix® (eftrenonacog alfa) in previously untreated patients (PUPs) with haemophilia A and B respectively will be